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Slowed processing speed is considered a hallmark feature of cognitive decline in cerebral small vessel disease (SVD); however, it is
unclear whether SVD’s association with slowed processing might be due to its association with overall declining general cognitive
ability. We quantified the total MRI-visible SVD burden of 540 members of the Lothian Birth Cohort 1936 (age: 72.6 ± 0.7 years; 47%
female). Using latent growth curve modelling, we tested associations between total SVD burden at mean age 73 and changes in
general cognitive ability, processing speed, verbal memory and visuospatial ability, measured at age 73, 76, 79 and 82. Covariates
included age, sex, vascular risk and childhood cognitive ability. In the fully adjusted models, greater SVD burden was associated
with greater declines in general cognitive ability (standardised β: −0.201; 95% CI: [−0.36, −0.04]; pFDR= 0.022) and processing
speed (−0.222; [−0.40, −0.04]; pFDR= 0.022). SVD burden accounted for between 4 and 5% of variance in declines of general
cognitive ability and processing speed. After accounting for the covariance between tests of processing speed and general
cognitive ability, only SVD’s association with greater decline in general cognitive ability remained significant, prior to FDR correction
(−0.222; [−0.39, −0.06]; p= 0.008; pFDR= 0.085). Our findings do not support the notion that SVD has a specific association with
declining processing speed, independent of decline in general cognitive ability (which captures the variance shared across domains
of cognitive ability). The association between SVD burden and declining general cognitive ability supports the notion of SVD as a
diffuse, whole-brain disease and suggests that trials monitoring SVD-related cognitive changes should consider domain-specific
changes in the context of overall, general cognitive decline.
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INTRODUCTION
Cerebral small vessel disease (SVD) is a major cause of cognitive
impairment in older adults. It causes ~25% of all strokes and is the
second most common cause of dementia after Alzheimer’s
disease, either on its own or through mixed pathologies [1, 2].
Caused by dysfunction of the brain’s arterioles, capillaries and
venules, the downstream effects of SVD are visible on neuroima-
ging as white matter hyperintensities (WMH) and lacunes of
presumed vascular origin, cerebral microbleeds and visible
perivascular spaces (PVS; see Fig. 1) [3]. In most individuals, these
radiological markers do not result in overt clinical symptoms;
however, their presence doubles the risk of stroke, and increases
the risk of dementia and death in the general population [4].
Despite its contribution to cognitive decline and to the develop-
ment of associated co-morbidities [4, 5], the precise nature of the
associations between the radiological burden of SVD and decline
in domain-specific cognitive abilities remains unclear.
Current consensus statements suggest that SVD is associated
with declining processing speed and executive function, alongside
relative preservation of memory and language abilities [6, 7].
However, previous studies examining domain-specific cognitive
decline in SVD have not accounted for the well-replicated
phenomenon in psychological research that cognitive test scores
typically correlate positively with one another, such that an
individual who performs well on a given cognitive test, is likely to
perform well on a broader range of tests [8]. This common
variance among test scores can be accounted for by general
cognitive ability, often termed ‘g’. General cognitive ability also
accounts for the majority of variance in domain-specific cognitive
decline; a recent meta-analysis estimated that, on average, 60% of
the variance in cognitive changes were shared across abilities [9].
It follows, therefore, that any domain-specific measure of cognitive
ability will be influenced not only by an individual’s ability in that
specific domain, but also by their overall level of general cognitive
ability. To be clear: if one finds an association between a
biomarker, or any other exposure, and scores on a domain of
cognitive ability or changes in a cognitive domain, there are three
possible reasons for the result. First, the association might be
wholly accounted for by an association with general cognitive
ability (on which all cognitive domains load substantially); second,
the association might be partly with general cognitive ability and
partly with the cognitive domain; and third, the association might
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indeed be exclusively with the cognitive domain. Thus, it is
necessary to test formally whether previously reported associa-
tions between SVD and processing speed are indeed specific to
that domain, rather than confounded by the phenomenon of
general cognitive ability.
To date, most studies investigating the relationship between
SVD brain changes and cognitive decline have focused on
individual radiological markers of SVD. WMH are the most
frequently investigated SVD marker, perhaps due to their
prevalence which is estimated at 64–94% in 82 year olds [10].
Recent meta-analyses report associations between greater base-
line WMH burden and steeper decline in both general and
domain-specific cognitive abilities, and greater risk of incident
dementia [4, 11]. Similarly, the presence of lacunes and micro-
bleeds have been associated with cognitive decline [12–14], but
associations between PVS and poorer cognitive ability, either
cross-sectionally or longitudinally, are more variable [12]. In recent
years, several studies have quantified the ‘total brain burden’ of
SVD using a simple 0–4 score, which allocates one point for the
presence of each SVD marker [15–18]. Whereas this approach goes
some way towards considering the potential cumulative impact of
different SVD markers on cognitive ability, the 0–4 score lacks
sensitivity to subtle differences in the severity of the individual
markers, and hence to their relative associations with cognitive
abilities.
To improve the fidelity of SVD burden quantification, two
previous studies (one using the same sample as the present study)
utilised continuous neuroimaging variables to construct continuous
SVD burden scores [19, 20]. In the first of these studies, Jokinen and
colleagues [19] demonstrated associations between SVD burden
(the average of standardised WMH, lacune, grey matter and
hippocampal volumes) and declining processing speed, executive
function, memory and general cognitive ability over a 3-year period.
In a subsequent study from our own research group, using data
from the LBC1936 [20], a continuous latent variable of SVD burden
was negatively associated with latent variables of processing speed,
verbal memory and visuospatial ability, in a structural equation
modelling framework (SEM). However, after accounting for the
shared variance between domain-specific scores (i.e. the variance
attributable to general cognitive ability), only the association with
processing speed remained. These findings suggest that the
apparent associations we observed between SVD burden and
domain-specific scores of verbal memory and visuospatial ability,
were largely due to the confounding associations between SVD
burden and general cognitive ability.
Longitudinal associations between SVD burden and declines in
specific domains of cognitive ability, independent of their associa-
tions with general cognitive ability, have yet to be examined. Here,
in a sample of relatively healthy older individuals, we investigate
associations between total MRI-visible SVD burden at age 73 and
Fig. 1 Key radiological markers of SVD examined in this study. Examples and schematic representations of key radiological features of SVD,
according to STRIVE guidelines [3]. Adapted with permission from ref. [3] [licence number 5094250830697, dated June 22 2021]. DWI diffusion-
weighted imaging, GRE gradient-recalled echo.
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longitudinal cognitive decline between the ages of 73 and 82, a
period that coincides with a substantial increase in dementia risk
[21]. Using growth curve modelling in a SEM framework, we
separate the variance in cognitive test scores attributable to general
cognitive ability from the variance attributable to the important,
ageing-relevant domains of processing speed, memory and
visuospatial ability. This enables us to test whether SVD-related
decline in specific cognitive domains are attributable to or
independent of declining general cognitive ability.
METHODS
This study uses data from the Lothian Birth Cohort 1936 (LBC1936), a
longitudinal study of cognitive, brain and general ageing [22]. In brief, the
LBC1936 is an ongoing follow-up study to the Scottish Mental Survey 1947
(SMS1947 [23]), which tested the cognitive abilities of 70,805 11-year-old
children who were born in 1936 and were attending school in Scotland in
1947. Between 2004 and 2007, 1091 individuals, most of whom had taken
part in the SMS1947, were recruited to the LBC1936. They have contributed
to up to five waves of data collection at mean ages of about 70 (n= 1091), 73
(n= 866), 76 (n= 697), 79 (n= 550) and 82 (n= 431) years. The present
study includes neuroimaging data from Waves 2, and cognitive data from
Waves 2–5 of the LBC1936 (there was no MRI at Wave 1). Wave 2 MRI data
were unusable for 51 of the 731 participants who underwent neuroimaging.
Images belonging to a further 140 participants exhibited noise or motion
artefacts that precluded the computational quantification of PVS, which due
to the small size of the PVS (<3mm), is highly sensitive to such artefacts.
Therefore, the remaining 540 participants constitute the baseline sample of
this study (see Fig. 2). Approvals for Waves 2–5 of the LBC1936 were obtained
from the Scotland A Research Ethics Committee for Scotland (07/MRE00/58).
All participants gave written, informed consent.
MRI data and the quantification of total SVD burden
The neuroimaging protocol for the LBC1936 has been published previously
[24]. Briefly, participants were scanned using a GE Signa Horizon HDx 1.5
Tesla clinical scanner (General Electric, Milwaukee, WI) operating in
‘research mode’, equipped with a self-shielding gradient set (33 mT/m
maximum gradient strength) and manufacturer supplied eight-channel
phased-array head coil. Sequences acquired were T1-weighted (T1W), T2-
weighted (T2W), T2*-weighted (T2*W) and fluid attenuated inversion
recovery-weighted (FLAIR) images. Scanner stability was monitored
throughout with a detailed quality assurance programme.
As previously reported, we used confirmatory factor analysis (CFA) to
construct a latent variable representing total MRI-visible SVD burden at
baseline (Wave 2 of the LBC1936 [20]). This latent variable comprised
continuous WMH volume (divided by total intracranial volume (TIV) to
account for differences in head size), continuous computationally derived
PVS count, and binary visual ratings of lacunes and microbleeds (i.e.
present/absent). Total WMH volume and TIV, were measured semi-
automatically using a validated multispectral image processing method
that combines T2*W and FLAIR sequences in the colour space for
enhanced feature discrimination in the segmentation [25], available from
https://sourceforge.net/projects/bric1936/. All slices of all scans were
checked by a trained observer and manually corrected, if necessary, to
ensure that no true WMH had been omitted and to avoid including
erroneous tissues in the WMH. PVS were computationally segmented in
the native T2W space in the centrum semiovale using a recently validated
technique [26, 27] and are presented as total number of PVS. All binary PVS
masks (superimposed on T2W images) were visually checked for the
accurate quantification of PVS by a trained operator and were accepted or
rejected blind to all other data. Where ambiguity arose, FLAIR and T1W
sequences were also checked. Lacunes and microbleeds were rated by an
experienced, registered neuroradiologist. Lacunes were defined as small
(>3mm and <2 cm in diameter) subcortical lesions of cerebrospinal fluid-
equivalent signal on T2W and decreased signal on T1W and FLAIR images
in the white matter, basal ganglia, and brainstem [3, 24]. Cerebral
microbleeds were defined as small (<5mm), homogeneous, round foci of
low signal intensity on T2*W images in the white matter, basal ganglia,
brainstem, cerebellum and cortico-subcortical junction [3, 24]. A random
20% sample of visual ratings and any uncertain cases were independently
checked by a second neuroradiologist, with disagreements resolved by
consensus. Owing to the scarcity of participants in our sample with more
than one lacune or microbleed (only 28/540 had >1 lacune, and only 65/
540 > 1 microbleed), both lacunes and microbleeds were modelled as
binary outcomes (i.e. present/absent).
Cognitive data
Participants completed the same series of cognitive tests at each wave of
data collection, in the same location, administered using the same
instructions. According to previous work examining their correlational
structure [28], we grouped cognitive tests into the following domains:
(1) Processing speed was measured using Digit Symbol Substitution and
Symbol Search from the Wechsler Adult Intelligence Scale-III (WAIS-III
UK [29]) and two experimental tasks: Inspection Time [30] and Four
Choice Reaction Time [31]. The Inspection Time task requires
participants to select the longer of two vertical lines that are flashed
on a computer screen for between 6 and 200 milliseconds. The
measure used here was the number of correct responses out of a total
of 150 trials. Four Choice Reaction Time scores were multiplied by
−1 so that higher scores indicated better performance.
(2) Memory consisted of Verbal Paired Associates (total score) and Logical
Memory (total score) from the Wechsler Memory Scale-III UK (WMS-III
UK [32]), and Backward Digit Span (WAIS-III UK).
(3) Visuospatial ability included Block Design and Matrix Reasoning (WAIS-
III UK) and Spatial Span (average of forwards and backwards; WMS-
III UK).
Our measure of general cognitive ability encompassed each of the
above-mentioned tests. The Moray House Test Number 12 (MHT), a 71-
item test of general cognitive ability, was also administered at the age of
11 as part of the Scottish Mental Survey 1947. In this study, we use the raw
MHT score, which can range from 0–76 and subsequently refer to this
variable as childhood cognitive ability.
Covariates
We included age in years, sex, vascular risk and childhood cognitive ability
in all models, in a stepwise manner. Vascular risk variables included self-
reported history of hypertension (yes/no); diabetes mellitus (yes/no);
smoking status (ever/never); blood-derived glycated haemoglobin (% total
HbA1c); blood-derived total cholesterol (mmol/l); and systolic and diastolic
blood pressure (average of six readings: three seated and three standing),
which were measured by trained nurses. We observed very little change in
vascular risk variables over the four waves of testing (see Table 1), possibly
as vascular risk factors such as hypertension and diabetes are relatively
well managed in the LBC1936. Therefore, we considered baseline (Wave 2,
age 73) vascular risk to be a sufficient representation of participants’
vascular status over the study period. We used CFA to construct a latent
variable representing vascular risk as previously modelled in the LBC1936
[33] and extracted its factor score for inclusion as a covariate. Childhood
cognitive ability accounts for approximately half of the variance in later life
cognitive ability [34]. In part, this association might be mediated by
increased SVD risk, which has also been found to associate with lower
childhood cognitive ability [35, 36]. Therefore, as we expect childhood
cognitive ability to attenuate the association between SVD burden and
cognitive abilities measured at the age of 73 (Wave 2), we included MHT
score measured at the age of 11 as a further covariate in our analyses.
Time-invariant covariates (sex, baseline vascular risk and childhood
cognitive ability) were regressed on the outcomes of interest (the general
and domain-specific cognitive intercepts and slopes) and were allowed to
covary with one another and with the latent SVD burden variable. We
specified time-variant covariates (age in years at each wave) as direct
predictors of the observed cognitive and MRI variables.
STATISTICAL ANALYSIS
Measurement models
First, we used hierarchical ‘factor-of-curves’ models (FoC) within a
SEM framework [37], as has been done previously in this cohort
[38, 39], to examine the initial level and subsequent decline in
general cognitive ability, processing speed, memory, and visuos-
patial ability between mean ages 73 (Wave 2), 76 (Wave 3), 79
(Wave 4) and 82 (Wave 5). A FoC model estimates the initial level
of each cognitive test (intercept) and its trajectory across all four
waves of testing (slope). The latent intercepts and slopes of each
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cognitive test load onto superordinate latent intercepts and latent
slopes of their respective cognitive domains (see Fig. 3A). This
permits analysis of the initial level and trajectory of each cognitive
domain as if they were directly observed.
Hierarchical factor-of-curves models of SVD-cognitive ability
associations
Next, we specified linear regressions between baseline (Wave 2)
SVD burden (independent variable) and the latent intercepts and
slopes (Waves 2–5) of general cognitive ability, processing speed,
memory and visuospatial ability (dependent variables). This was
carried out in separate hierarchical FoC models: one for general
cognitive ability, and one for each cognitive domain. Importantly,
it should be noted that at this stage the cognitive domains will
contain any variance actually attributable to general cognitive
ability (i.e. common across cognitive domains). Associations
between SVD burden and latent cognitive intercepts approximate
the cross-sectional associations that we reported previously [20].
Fig. 2 Consort diagram illustrating the selection of the study sample.
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Therefore, in this study we are primarily interested in the
associations between SVD burden and the latent cognitive slopes.
Longitudinal bifactor models of SVD-cognitive ability
associations: accounting for covariance between domain-
specific scores and general cognitive ability
Previous analyses in the LBC1936 have estimated that general
cognitive ability explains ~50% of the variability in the decline of
individual test scores between the ages of 70 and 76, and up to
70% of variability in their decline between 70 and 79 [38, 40].
Owing to this shared variability, estimations of decline in any
measure of domain-specific cognitive ability will contain both the
amount of decline in that domain-specific ability and the amount
of decline in general cognitive ability. Therefore, to assess decline
in domain-specific cognitive abilities, the variance in test scores
associated with general cognitive ability must be removed. To do
this, we constructed a longitudinal bifactor model (in a SEM
framework) in which the variance associated with general and
domain-specific abilities is parsed into separate latent variables, so
that the level and trajectory of general cognitive ability and those
of the domain-specific abilities can be measured independently of
one another (see Fig. 3B). To test associations between SVD
burden and the level and decline of domain-specific abilities
independently of general ability, we specified linear regressions
between SVD burden (independent variable) and the latent
intercepts and slopes of the cognitive variables (general cognitive
ability and the three cognitive domains) from the longitudinal
bifactor model.
Examining the contribution of WMH to the total SVD burden-
cognitive ability associations
Of the radiological markers of SVD examined here, WMH are the
most regularly associated with poorer cognitive abilities. It is
plausible, therefore, that any associations between the SVD
burden variable and cognitive factors could largely be driven
WMH. To test whether this was the case, we repeated the
hierarchical FoC analyses with WMH/TIV in the place of SVD
burden as the predictor variable. As an indication of the relative
utility of total SVD burden and WMH/TIV as predictors of cognitive
outcomes, we examined the magnitude of standardised effect
sizes and confidence intervals of models specifying WMH/TIV, and
those of models specifying total SVD burden as the predictor.
As absolute fit indices are unavailable when using maximum
likelihood to estimate models including binary measures, we
assessed the fit of models specifying total SVD burden as the
predictor (binary measures of lacunes and microbleeds contribute
Table 1. Characteristics of study completers only, at each wave.
n Wave 2 n Wave 3 n Wave 4 n Wave 5
Sociodemographic
Age, years 300 72.5 (0.7) 297 76.2 (0.7) 296 79.3 (0.6) 300 82.0 (0.5)
Female, n (%) 300 147 (49.0%) 300 145 (48.8%) 296 143 (48.3%) 300 147 (49.0%)




300 135 (45.0%) 297 157 (52.9%) 296 172 (58.1%) 300 176 (58.7%)
Systolic blood
pressure, mmHg
297 145.6 (18.0) 293 146.4 (17.5) 291 144.2 (17.9) 294 147.2 (20.2)
Diastolic blood
pressure, mmHg
297 79.4 (9.2) 293 80.0 (9.4) 291 78.4 (9.5) 294 78.6 (10.5)
Diabetes history, n (%) 300 20 (6.7%) 297 26 (8.8%) 296 31 (10.5%) 300 33 (11.0%)
HbA1c, mmol/mol 290 38.8 (5.8) 283 40.7 (7.1) 281 40.5 (7.9) 280 40.2 (8.0)
Cholesterol, mmol/l 291 5.3 (1.1) 275 5.1 (1.2) 287 5.1 (1.1) 284 4.9 (1.2)
Cardiovascular disease
history, n (%)
300 83 (27.7%) 297 103 (34.7) 296 110 (37.2%) 298 118 (39.6)
Smoking status, n (%) 300 Ever= 141 (47.0%);
Never= 159
(55.0%)
297 Ever= 134 (45.1%);
Never= 163
(54.9%)







Moray House Test age-11
(max. 76)
283 51.2 (11.5) 280 51.2 (11.5) 279 51.3 (11.5) 283 51.2 (11.5)
Neuroimaging
Total WMH volume cm3 298 10.5 (11.3) 258 14.8 (14.6) 252 19.2 (16.9) 241 22.4 (18.8)
Total brain volume cm3 300 991.9 (87.2) 258 976.0 (86.8) 252 964.4 (88.0) 241 947.3 (85.5)
PVS count 300 251.8 (92.5)
Lacunes, n (%) 300 Present= 13
(4.3%); Absent=
287 (95.7%)
Microbleeds, n (%) 300 Present= 33
(11.0%); Absent=
267 (89.0%)
Values are mean (standard deviation) unless otherwise specified. Three participants did not take part in Wave 3 only and four participants did not take part in
Wave 4 only.
PVS visible perivascular spaces, WMH white matter hyperintensities of presumed vascular origin.
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to the latent SVD variable) against a less-restrictive neighbouring
model (i.e. one in which latent SVD burden, latent cognitive
intercepts and latent cognitive slopes were permitted to correlate
with one another) using the likelihood ratio test statistic calculated
as follows: −2 × (loglikelihood of the less-restrictive model−
loglikelihood of full model). For models specifying WMH/TIV as the
predictor, model fit was assessed using four absolute fit indices:
Root Mean Square Error of Approximation (RMSEA; < 0.06
considered acceptable), Comparative Fit Index (CFI; > 0.95 accep-
table), Tucker-Lewis Index (TLI; > 0.95 acceptable), and Standar-
dised Root Mean Square Residual (SRMR; < 0.08 acceptable [41]).
All analyses were carried out in MPlus version 8.4 [42] and were
estimated using Full Information Maximum Likelihood (FIML),
which estimates model parameters based on all available data
from our sample of 540 LBC1936 participants. We corrected p-
values for multiple comparisons using the False Discovery Rate
adjustment (FDR [43]), with p.adjust in R version 4.0.1 [44]. This
correction was carried out separately for p-values from three
different groups of models: (1) associations between total SVD
burden and the intercept and slopes of cognitive change from
hierarchical FoC models; (2) associations between WMH/TIV and
the intercept and slopes of cognitive change from hierarchical FoC
models; (3) associations between total SVD burden and the
intercept and slopes of cognitive change from bifactor models.
RESULTS
Cohort characteristics
Sociodemographic and clinical characteristics for study completers
only at each wave are shown in Table 1, highlighting changes in
the same sample over the four waves. Characteristics for all
participants at each wave are presented in Table 2. We included
540 participants at baseline and lost between 13 and 16% of
participants to follow-up at each subsequent wave. Participants
lost to follow-up had a higher baseline prevalence of diabetes (but
slightly lower cholesterol levels), greater total WMH volume, fewer
years of education, and slightly lower childhood cognitive ability
than study completers (see Table S1).
Cognitive decline effect sizes between age 73 and 82
We first modelled the mean change in general cognitive ability,
processing speed, memory and visuospatial ability between the
ages of 73 and 82 in separate hierarchical FoC models. Note that,
at this stage, the cognitive domains will still contain any variance
due to general cognitive ability. Table S2 provides details of the
initial levels (intercepts) and trajectories (slopes) for each cognitive
domain. All cognitive domain scores showed a significant mean
decline over the nine-year period (all p < 0.001). In standard
deviation units, the declines per year were: −0.13 (just under 2 IQ
points, which each have a SD of 15) for general cognitive ability,
−0.16 for processing speed, −0.005 for memory and −0.08 for
visuospatial ability.
Total SVD burden associations with declines in general
cognitive ability and cognitive domains in separate factor-of-
curves models
The key analyses in this study were associations between total
SVD burden and trajectories of general cognitive ability, proces-
sing speed, verbal memory and visuospatial ability. Note that in
the hierarchical FoC models, the domains still contain any variance
due to general cognitive ability. After the inclusion of covariates,
total SVD burden was negatively associated with the slope of
general cognitive ability (standardised β: −0.201; 95% CI: [−0.36,
−0.04]; p= 0.015; pFDR= 0.022) and processing speed (−0.222;
[−0.40, −0.04]; p= 0.015; pFDR= 0.022), but not with verbal
memory or visuospatial ability (see Table 3). R2 values indicated
that total SVD burden accounted for ~4% of the variance in the
slope of general cognitive ability, and 5% of the variance in the
slope of processing speed (which still contains general cognitive
ability variance). In line with our previously reported results [20],
total SVD burden was negatively associated with the intercept of
all cognitive variables after the inclusion of covariates:
Fig. 3 Illustrations of a hierarchical ‘factor-of-curves’ model and a longitudinal bifactor model of cognitive ability. A Example of a
hierarchical ‘Factor-of-Curves’ (FoC) model of cognitive ability. For the hierarchical FoC models, a growth curve was estimated for each
individual cognitive test, producing a latent intercept and slope. These test-specific latent intercepts and slopes, in turn, loaded onto an
overall latent intercept and slope for the cognitive domain. Loadings on the slopes were set to 0, 3.78, 6.83, and 9.55, to reflect the average
time lags between baseline and subsequent waves. In this illustration we also show how we specified associations between latent SVD burden
and the intercept and slope of the cognitive factor (see dashed lines), and how we included additional time-invariant (sex, vascular risk,
childhood cognitive ability) and time-variant (age) covariates (see items in grey). Separate models were carried out for each cognitive domain
(i.e. general cognitive ability, processing speed, verbal memory, and visuospatial ability). Following conventional SEM notation, variables in
squares were observed and measured, and variables in circles represent unobserved latent variables. Single headed arrows represent
specified relationships between variables and double headed arrows represent correlations. B Example of a longitudinal bifactor model of
cognitive ability. In the centre of the model are the latent intercept and slope of each cognitive test, which were constructed using latent
growth curves of the originally observed test scores at each time point (as described in the panel A note). The variance in these test-specific
latent intercepts and slopes is separated into that which contributes to the latent intercept and slope of each cognitive domain, and that
which contributes to the latent intercept and slope of general cognitive ability. We tested associations between total SVD burden and the
intercept and slope of each cognitive variable simultaneously (not shown in this illustration). Additional time-invariant and time-variant
covariates were included as indicated for the hierarchical FoC model (not shown in this illustration, see panel A for details).
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(standardised betas ranged between −0.322 to −0.173; pFDR ≤
0.022; for full results see Table S3).
Total SVD burden associations with declines in general
cognitive ability and specific cognitive domains, modelled
simultaneously in a longitudinal bifactor model
We next tested associations between total SVD burden and
cognitive variables using a bifactor model, which separates out
the variance in cognitive test scores attributable to general
cognitive ability and to domain-specific factors (see Table 4).
Results of the fully adjusted bifactor model indicated that total
SVD burden was associated with greater decline (steeper down-
ward slope) in general cognitive ability only prior to FDR
correction (standardised β: −0.222; 95% CI: [−0.39, −0.06]; p=
0.008; pFDR= 0.085). We found no significant associations between
total SVD burden and the slopes of any other cognitive variables
(i.e. processing speed, verbal memory or visuospatial ability) in the
bifactor model. In terms of SVD-cognitive intercept associations,
total SVD burden was associated with the intercept of general
cognitive ability only, but this association became non-significant
after the inclusion of covariates and adjustment for FDR (see Table
S4).
Finally, we tested whether the associations observed between
SVD burden and cognitive decline were likely driven by the
contribution of WMH to the SVD burden score. We re-ran the
hierarchical FoC models with WMH/TIV in the place of total SVD
burden as the predictor (for results see Tables S5 and S6). Note
that in the hierarchical FoC models, the domains will still contain
any variance due to general cognitive ability. In the fully adjusted,
FDR-corrected models, we observed significant associations
between WMH/TIV and the slopes of general cognitive ability
(standardised β: −0.149; 95% CI: [−0.26, −0.04]; p= 0.008; pFDR=
0.012) and processing speed (standardised β: −0.176; 95% CI:
[−0.30, −0.05]; p= 0.007; pFDR= 0.012). Effect sizes of these
models were 0.052 and 0.046 standard deviations smaller (for
general cognitive ability and processing speed, respectively) than
models specifying total SVD burden as the predictor, and
confidence intervals from models using different predictors
overlapped substantially. Differences in effect size magnitudes
were more pronounced for the total SVD-cognitive intercept
associations; effect sizes of models with WMH/TIV as the predictor
were between 0.105 and 0.117 standard deviations smaller than
models with total SVD burden as the predictor. Overlap between
confidence intervals of these models was present but more
modest than for slopes.
DISCUSSION
In this longitudinal study of 540 community-dwelling older adults,
we investigated associations between the total MRI-visible burden
of cerebral SVD and the nine-year trajectory of cognitive abilities
between the ages of 73 and 82. We found associations between
Table 2. Characteristics of the study sample at each wave.
n Wave 2 (n= 540) n Wave 3 (n= 463) n Wave 4 (n= 372) n Wave 5 (n= 300)
Sociodemographic
Age, years 540 72.5 (0.5) 463 76.2 (0.7) 372 79.5 (0.6) 300 82.0 (0.5)
Female, n (%) 540 252 (46.7%) 463 217 (46.9%) 372 195 (52.4%) 300 147 (49.0%)
Education, years 540 10.9 (1.2) 463 10.9 (1.2) 372 10.9 (1.2) 300 11.0 (1.2)
Vascular risk
Hypertension history, n (%) 540 259 (48.0%) 462 251 (54.3%) 372 218 (58.6%) 300 176 (58.7%)
Systolic blood
pressure, mmHg
534 146.5 (18.0) 458 147.4 (18.5) 366 144.2 (17.9) 294 147.2 (20.2)
Diastolic blood
pressure, mmHg
534 79.7 (18.0) 458 80.3 (9.8) 366 78.2 (9.7) 294 78.6 (10.5)
Diabetes history, n (%) 540 54 (10.0%) 463 52 (11.2%) 371 42 (11.3%) 300 33 (11.0%)
HbA1c mmol/mol 518 39.0 (6.4) 438 40.8 (7.1) 348 40.4 (8.0) 280 40.2 (8.0)
Cholesterol, mmol/l 521 5.2 (1.1) 426 5.0 (1.2) 360 5.0 (1.2) 284 4.9 (1.2)
Cardiovascular disease
history, n (%)
540 154 (28.5%) 463 152 (32.8%) 372 135 (36.3%) 298 118 (39.6)
Smoking status, n (%) 540 Ever= 274 (50.7%);
Never= 266
(49.3%)
462 Ever= 218 (47.2%);
Never= 244
(52.8%)







Moray House Test age-11
(raw score, max 76)
511 50.2 (11.9) 437 50.9 (11.6) 372 51.1 (11.7) 283 51.2 (11.5)
Neuroimaging
WMH volume cm3 537 12.2 (12.8) 387 16.4 (15.3) 309 20.5 (17.7) 241 22.4 (18.8)
Total brain volume cm3 533 993.7 (88.4) 387 976.4 (88.5) 309 965.4 (87.0) 241 947.3 (85.5)
PVS count 540 258.7 (94.6)
Lacunes, n (%) 540 Present= 28 (5.1%);
Absent= 512
(94.9%)
Microbleeds, n (%) 540 Present= 65
(12.0%); Absent=
475 (88.0%)
O.K.L. Hamilton et al.
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greater SVD burden and greater decline in both general cognitive
ability and processing speed, after accounting for age, sex,
vascular risk and childhood cognitive ability. We then separated
the variance in cognitive test scores attributable to domain-
specific abilities and to general cognitive ability (using a bifactor
model), to test SVD’s relationship with declining processing speed,
independent of the influence of general cognitive decline. In the
fully adjusted bifactor model, the association between greater SVD
burden and declining general cognitive ability was nominally
significant (p= 0.008), but became non-significant after FDR
correction (pFDR= 0.085). In contrast, in the bifactor model the
negative association between total SVD burden and declining
processing speed was non-significant both prior to and following
FDR correction (p= 0.599; pFDR= 0.943). We were cautious in our
use of FDR correction; smaller p-values in the bifactor models were
heavily penalised due to the large number of p-values included in
the correction. In addition to the non-zero-containing confidence
intervals for this association, the overall results from this bifactor
model suggest that SVD burden’s association with declining
processing speed might be accounted for by overall decline in
general cognitive ability. By overlooking the shared variance
among domain-specific cognitive tests, previously observed
associations between radiological markers of SVD and decline in
domain-specific abilities could be an artefact of the relationship
between SVD markers and declining general cognitive ability.
Alongside these main results, in the hierarchical FoC models we
observed associations between total SVD burden and the initial
levels of general cognitive ability, processing speed, verbal
memory and visuospatial ability at the age of 73. These results
are in line with our previous analyses that used only cross-
sectional data from age 73 [20].
Effect sizes for associations between total SVD burden and
greater decline in general cognitive ability and processing speed
(before accounting for their covariance), were medium sized
(standardised betas were −0.201 and −0.222 respectively) [45].
These relatively modest effect sizes are unsurprising considering
the huge number of additional structural brain variables, such as
decreasing white matter microstructural integrity and cortical
volumes, that contribute to cognitive decline in later life [39, 46].
The addition of age, sex, vascular risk and childhood cognitive
ability did not attenuate these effect sizes. The lack of attenuation
is expected as it has been observed previously in the LBC1936 that
childhood cognitive ability is strongly associated with levels of
cognitive ability in later life, but not with cognitive decline [38].
Additionally, combined vascular risk factors measured in later life
only account for ~2% of the variance in WMH in the LBC1936 [47]
(see also [48]), and individually, factors such as a diagnosis of
hypertension, diabetes, or cardiovascular disease have shown no
unique association with cognitive decline in this sample [28, 38].
That SVD burden appears to be associated with an overall
decline in general cognitive ability (after accounting for covar-
iance between general and domain-specific test scores) is
consistent with the pattern of non-pathological, age-related
cognitive decline. Previous studies have estimated that the
majority of the variance in age-related decline across domain-
specific cognitive abilities is shared, and that the proportion of
shared variance increases with age (up to 70% by the age of 85)
[9, 38]. This implies that to a large and increasing extent, different
Table 3. Factor-of-curves models of associations between total SVD burden and the slope of latent cognitive variables between the ages of 73 and
82a.
Slope
Standardised β (SE) 95% CI Uncorrected p-value FDR-corrected p-
valueb
General cognitive ability −0.191 (0.08) −0.351, −0.031 0.019 0.026
+ age + sex −0.200 (0.08) −0.358, −0.042 0.013 0.022
+ age + sex + vascular risk −0.198 (0.08) −0.355, −0.041 0.013 0.022
+ age + sex + vascular risk + childhood cognitive
ability
−0.201 (0.08) −0.363, −0.039 0.015 0.022
Processing speed −0.189 (0.09) −0.364, −0.013 0.035 0.047
+ age + sex −0.223 (0.09) −0.399, −0.046 0.013 0.022
+ age + sex + vascular risk −0.222 (0.09) −0.397, −0.047 0.013 0.022
+ age + sex + vascular risk + childhood cognitive
ability
−0.222 (0.09) −0.401, −0.044 0.015 0.022
Verbal memory −0.139 (0.10) −0.340, 0.061 0.174 0.223
+ age + sex −0.092 (0.11) −0.302, 0.117 0.388 0.428
+ age + sex + vascular risk −0.094 (0.11) −0.304, 0.115 0.377 0.428
+ age + sex + vascular risk + childhood cognitive
ability
−0.102 (0.11) −0.315, 0.110 0.345 0.410
Visuospatial ability −0.179 (0.22) −0.602, 0.245 0.408 0.435
+ age + sex −0.157 (0.22) −0.579, 0.265 0.466 0.466
+ age + sex + vascular risk −0.162 (0.22) −0.589, 0.265 0.457 0.466
+ age + sex + vascular risk + childhood cognitive
ability
−0.171 (0.18) −0.527, 0.185 0.346 0.410
Four separate models were run for each cognitive factor, adding covariates in a stepwise manner. Likelihood ratio test statistic (LR) and degrees of freedom
(DF) for each of the unadjusted models were as follows: General cognitive ability (LR= 6.79; DF= 30), processing speed (LR= 0.22; DF= 2), verbal memory (LR
= 2.95; DF= 1), visuospatial ability (LR= 1.54; DF= 2). SVD burden-cognitive intercept associations from these models are presented in Table S3.
CI confidence interval, FDR false discovery rate, SE standard error.
aNote that the cognitive domains will contain any variance due to general cognitive ability.
bFDR correction was conducted across results presented in this table and in Table S3.
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domains of cognitive ability will decline together with advancing
age. As age is the most important risk factor for SVD, it follows that
SVD-related decline in domain-specific cognitive abilities are likely
attributable to cognitive decline more generally. When examining
associations between SVD burden and cognitive decline, our
results suggested that SVD burden was associated with decline in
general cognitive ability and processing speed only. However, it
would be inaccurate to conclude from this that SVD-related
cognitive decline does not involve declining visuospatial and
memory abilities, as variance associated with decline in memory
and visuospatial tests is well represented in the latent slope of
general cognitive ability.
The potential association between SVD burden and overall
decline in general cognitive ability also supports the notion of SVD
as a diffuse, whole-brain disease that disrupts or ‘disconnects’
regions of the brain that sub-serve our cognitive abilities [49, 50].
Diffusion imaging (dMRI), which quantifies the diffusion of water
molecules, thus providing a measurement of the microstructural
organisation of the brain’s white matter, has demonstrated that
SVD-related structural changes extend beyond visible radiological
markers of the disease into the ‘normal appearing’ tissue that
surrounds the visible lesion [51–53]. Radiological markers of SVD
are also known to have deleterious effects on areas remote from
the lesion site; lacunes have been associated with thinning of the
overlying cortical area, possibly due to degradation of the
connecting white matter fibres [54]. Widespread alterations of
white matter connections have been associated with poorer
cognitive abilities directly [55, 56], and have also been highlighted
by studies applying graph theoretic approaches to dMRI
tractography data as a potential determinant of cognitive
impairments via reduced density of white matter connections
and impaired efficiency of information transfer between different
brain regions [57–59].
To test whether associations between total MRI-visible SVD
burden and cognitive outcomes were driven primarily by the
contribution of WMH burden to the total SVD burden variable, we
re-ran our hierarchical FoC models specifying WMH volume as the
predictor. WMH volume was associated with the intercept of all
cognitive factors, however, the magnitudes of effect sizes of these
models were smaller (by between 0.11 and 0.12 standard
deviations, with 95% CIs slightly overlapping) than those from
models specifying SVD burden as the predictor. This suggests that
total SVD burden could be a more powerful predictor of cognitive
performance cross-sectionally than WMH burden alone. Interest-
ingly, this was not the case when modelling cognitive decline;
differences between the effect sizes of models specifying total
SVD burden vs. WMH/TIV as the predictor of decline in cognitive
outcomes appeared to be more modest (differences of between
0.046 and 0.052 standard deviations, with 95% CIs largely
overlapping). Whereas incorporating measurements of PVS,
lacunes and microbleeds alongside WMH in a single SVD burden
score appears to strengthen the prediction of cognitive outcomes
cross-sectionally, doing so may provide limited predictive power
beyond that of WMH volume alone in associations with cognitive
change between the ages of 73 and 82. WMH on neuroimaging
represent heterogenous changes in the underlying brain tissue
and cerebral microvasculature, ranging from alterations in water
content and the build-up of perivascular oedema, which can
resolve over time, to demyelination and axonal degeneration,
which likely cannot [2]. On the one hand, even though WMH are
Table 4. Results of bifactor models of associations between total SVD burden and slope of latent cognitive variables between age 73 and 82.
Slope
Standardised β (SE) 95% CI Uncorrected p-value FDR-corrected p-
valuea
General cognitive ability −0.204 (0.08) −0.366, −0.042 0.014 0.112
+ age + sex −0.224 (0.08) −0.386, −0.062 0.007 0.085
+ age + sex + vascular risk −0.223 (0.08) −0.385, −0.062 0.007 0.085
+ age + sex + vascular risk + childhood cognitive
ability
−0.222 (0.08) −0.387, −0.057 0.008 0.085
Processing speed 0.057 (0.17) −0.265, 0.380 0.728 0.971
+ age + sex −0.067 (0.16) −0.382, 0.249 0.678 0.943
+ age + sex + vascular risk −0.071 (0.16) −0.389, 0.248 0.664 0.943
+ age + sex + vascular risk + childhood cognitive
ability
−0.087 (0.17) −0.410, 0.236 0.599 0.943
Verbal memory −0.078 (0.11) −0.298, 0.141 0.483 0.871
+ age + sex 0.012 (0.12) −0.223, 0.247 0.919 0.982
+ age + sex + vascular risk 0.012 (0.12) −0.224, 0.247 0.922 0.982
+ age + sex + vascular risk + childhood cognitive
ability
0.007 (0.12) −0.231, 0.245 0.955 0.982
Visuospatial ability 0.191 (0.28) −0.352, 0.734 0.490 0.871
+ age + sex 0.120 (0.27) −0.399, 0.638 0.650 0.943
+ age + sex + vascular risk 0.125 (0.26) −0.392, 0.642 0.636 0.943
+ age + sex + vascular risk + childhood cognitive
ability
0.065 (0.26) −0.444, 0.574 0.803 0.982
Each bifactor model estimates associations between SVD burden and the four cognitive variables simultaneously. Four bifactor models were run: one without
covariates, then three further models including covariates in a stepwise manner. Likelihood ratio test statistic (LR) and degrees of freedom (DF) for the
unadjusted model was as follows: LR= 55.3; DF= 9. CI: confidence interval; FDR: false discovery rate; SE: standard error. SVD burden-cognitive intercept
associations from these models are presented in Table S4.
CI confidence interval, FDR false discovery rate, SE standard error.
aFDR correction was conducted across results presented in this table and in Table S4.
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dynamic in nature [60], as one of the earliest radiological features
of SVD, extensive WMH could indicate a longer duration of disease
processes, thus could be more strongly related to detectable
clinical features such as cognitive decline. On the other hand,
other radiological markers of SVD such as lacunes and cerebral
microbleeds, which represent more established vascular damage,
are relatively uncommon in our study sample. Therefore, in a
population of individuals with more severe SVD pathology, a
variable representing total SVD burden may have more predictive
power in relation to cognitive change. Additionally, the latent SVD
burden variable represents only the shared variance between the
four MRI markers of SVD. If the variance unique to each MRI
marker of SVD also associates with cognitive change, the fact that
it is not represented in our latent SVD burden variable may limit
the magnitude of associations between the SVD burden variable
and cognitive slopes.
This study benefits from the availability of multiple waves of in-
depth cognitive testing in a relatively large sample of individuals,
over almost a decade of time. In-depth biological and clinical
phenotyping in the LBC1936 also enabled us to account for a
broad range of vascular risk variables. A further strength of the
LBC1936 is the availability of a measure of childhood cognitive
ability. By including childhood cognitive ability as a covariate in
our models, we were able to eliminate its confounding effects on
associations between SVD burden and later life cognitive abilities.
Our study also has several limitations. Members of the LBC1936
are self-selecting, so represent a generally healthy, well-educated
and highly motivated sample and mostly have a mild, non-clinical
presentation of SVD. The main effect of this is probably a slight
lowering of true effect sizes [61]. It could be the case, therefore,
that we are underestimating the associations between SVD
burden and cognitive decline. However, that we observe
associations between SVD burden and cognitive decline in a
relatively healthy population of older individuals who are mostly
free of overt cognitive impairment, demonstrates that SVD-related
cognitive decline is present even before clinical presentation. A
limitation of the longitudinal study design is that participants who
dropped out of the study before Wave 5 may have done so due to
poor health outcomes related to SVD (i.e. stroke or dementia).
Indeed, study non-completers had significantly greater baseline
WMH volumes than participants who remained in the study up to
Wave 5 (see Table S1). To some extent, we have been able to
mitigate this survivor bias by using FIML as our model estimator,
thus including all available data from our sample of 540 LBC1936
participants and ensuring that our results were not overly biased
by the healthier participants of the initial 540, who completed all
waves. A further limitation of the study was that we were unable
to include 140 LBC1936 participants due to the inability to obtain
PVS segmentation due to noise or imaging artefacts. In
comparison with the study sample, the excluded sample were
slightly older, had fewer years of education, had a higher
prevalence of smoking status (ever vs. never), and lower age-11
IQ (see Table S7). However, the excluded sample also had a lower
prevalence of self-reported cardiovascular disease, lower white
matter hyperintensity volume, greater total brain volume, and did
not differ significantly in their burden of lacunes or cerebral
microbleeds.
In this study we observed associations between the total MRI-
visible burden of SVD and decline in general cognitive ability. The
association we observed between SVD burden and decline in
processing speed appears to be due to the overarching
association between SVD burden and declining cognitive ability
more generally. When monitoring SVD-related cognitive decline,
trials of treatments or interventions for SVD should carry out an in-
depth measure of general cognitive ability (i.e. as opposed to a
brief screening instrument) alongside assessments of any specific
cognitive domain that is of particular interest. In doing so, any
domain-specific cognitive changes can be examined in the
context of declining general cognitive ability.
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